Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

OBJECTIVE: To assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. METHODS: A 3-year budget impact analysis model was adapted to estimate the cost of introducing biosim...

Descripción completa

Detalles Bibliográficos
Autores principales: Calleja, Miguel Angel, Albanell, Joan, Aranda, Enrique, García-Foncillas, Jesús, Feliu, Anna, Rivera, Fernando, Oyagüez, Itziar, Salinas-Ortega, Laura, Soto Alvarez, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086713/
https://www.ncbi.nlm.nih.gov/pubmed/34810173
http://dx.doi.org/10.1136/ejhpharm-2021-002955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086713/
https://www.ncbi.nlm.nih.gov/pubmed/34810173
http://dx.doi.org/10.1136/ejhpharm-2021-002955

Ejemplares similares